Zilucoplan

Zilucoplan (Zilbrysq) is a fully synthetic macrocyclic peptide that blocks the same complement protein — C5 — as antibody drugs like eculizumab, but does it as a small, self-injectable peptide instead of a monoclonal antibody requiring an infusion center. FDA-approved in October 2023 for generalized myasthenia gravis on the strength of a real Phase 3 trial, it carries the same boxed warning as every other C5 inhibitor: a real, mechanism-driven risk of meningococcal infection.

A peptide doing an antibody drug's job

Zilucoplan is a fully synthetic macrocyclic peptide — 15 amino acids, including four non-natural ones, closed into a ring, with a lipid tail attached through a short PEG linker to extend its time in the body enough for once-daily dosing.³ It binds human complement component 5 (C5) and blocks the C5 convertase enzyme from cleaving it into C5a and C5b, the two fragments that drive the destructive, antibody-triggered attack on the neuromuscular junction seen in generalized myasthenia gravis (gMG). That target is the same one blocked by eculizumab and ravulizumab, both monoclonal antibodies given by IV infusion at an infusion center — zilucoplan reaches the identical target, but as a small peptide a patient injects at home, once a day, in a few seconds. It's also structurally unrelated to icatibant and ecallantide, this site's other peptide-based complement-adjacent drugs, which work through the separate bradykinin/kallikrein pathway rather than C5.

The RAISE trial

The pivotal Phase 3 RAISE trial randomized 174 adults with anti-acetylcholine-receptor-antibody-positive gMG to daily self-injected zilucoplan (0.3 mg/kg) or placebo for 12 weeks. The least-squares mean change in the MG-ADL activities-of-daily-living score — the trial's primary endpoint, where a bigger drop means less disease burden — was -4.39 with zilucoplan versus -2.30 with placebo, a difference of -2.09 points (95% CI -3.24 to -0.95; p=0.0004) (Howard JF Jr, Bresch S, Genge A, et al., "Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study," Lancet Neurol 2023;22(5):395-406, PMID 37059508, DOI: 10.1016/S1474-4422(23)00080-7).¹ Secondary outcomes — a clinician-rated severity score and a quantitative strength-testing score — moved the same direction, and benefit was apparent within the first week of dosing. That's a real, published, adequately powered placebo-controlled result, not an open-label or single-arm study.

A drug that started out for a different disease entirely

Zilucoplan wasn't originally developed for myasthenia gravis. Ra Pharmaceuticals discovered it (under the code RA101495) and first tested it in small, open-label Phase 2 studies in paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where uncontrolled complement activity destroys red blood cells — the same disease eculizumab was first approved for — before running a separate Phase 2 trial in generalized myasthenia gravis that succeeded and became the company's lead indication instead. UCB acquired Ra Pharmaceuticals for roughly $2.3 billion in a deal completed 2 April 2020, bringing zilucoplan (and Ra's antibody candidate rozanolixizumab, later separately approved for gMG too) into UCB's neurology pipeline — the approvals that followed in 2023 came under UCB's ownership, not Ra Pharmaceuticals' original one.

The boxed warning: a real, mechanism-driven risk, not unique to this drug

This isn't a flaw specific to zilucoplan — it's the mechanistic cost of blocking C5 by any method, antibody or peptide, and every other approved C5 inhibitor carries the identical warning. It's a genuine, serious risk that anyone considering this drug class needs to take seriously, managed through vaccination and monitoring rather than something that makes zilucoplan worse or better than its antibody-based alternatives.

Current status

Zilucoplan's first approval anywhere was actually in Japan, in September 2023, ahead of the US approval the following month and an EU approval in December 2023 as an add-on to standard gMG therapy. It has been commercially available in the US since shortly after its October 2023 approval, prescribed for adult, AChR-antibody-positive generalized myasthenia gravis under UCB. An open-label extension study (RAISE-XT) has continued reporting on long-term safety and durability of effect since. There is no wellness, off-label bodybuilding or grey-market interest in zilucoplan of any kind we could find — a REMS-restricted specialty neurology drug prescribed and monitored by a treating physician, not something available outside that channel.